# BioVersys reports results from Phase 2a ENABLE study for tuberculosis treatments containing AlpE

- Source: PR Newswire M&A
- Published: 2026-11-20T06:24:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/bioversys-reports-results-from-phase-2a-enable-study-for-tuberculosis-treatments-containing-alpe-302946581.html
- Canonical: https://groundlevelnews.com/story/bioversys-reports-results-from-phase-2a-enable-study-for-tuberculosis--0ece99/

Phase 2a ENABLE study showed early bactericidal activity in all regimens evaluated over 14 days in patients with newly diagnosed drug-sensitive pulmonary tuberculosis AlpE combined with RZE achieved early bactericidal activity comparable to standard-of-care HRZE over 14 days Findings...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._
